NEUROVIVE
NeuroVive Pharmaceutical AB
Application Filed: 2018-11-09
Trademark Application Details
NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
| Research |
OneLook
Acronym Finder
|
| Serial Number | 79250595 |
| Registration Number | 6109809 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
Timeline
| 2018-11-09 | Application Filed |
| 2019-01-31 | Location: INITIAL REVIEW/SERIALIZATION BRANCH(MAILROOM) |
| 2019-01-31 | Status: Live/Pending |
| 2019-02-06 | Transaction Date |
| 2020-07-28 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  NeuroVive Pharmaceutical AB |
| Address | Medicon Village, Scheelevägen 2; SE-223 81 Lund XP |
| Legal Entity Type | Limited Liability Company |
| Legal Entity State | XP |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 1 |
| U.S. Codes: | 001,005,006,010,026,046 |
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 9 |
| U.S. Codes: | 021,023,026,036,038 |
| International Codes: | 10 |
| U.S. Codes: | 026,039,044 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| International Codes: | 44 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0011 | Esters for veterinary use; esters for veterinary purposes; esters for foodstuffs, not for pharmaceutical purposes |
| GS0051 | Acetates for pharmaceutical purposes; acids for pharmaceutical purposes; adjuvants for medical purposes; aldehydes for pharmaceutical purposes; alginates for pharmaceutical purposes; amino acids for medical purposes; amino acids for veterinary purposes; antibiotics; antidiabetic pharmaceuticals; food supplements, namely, antioxidant pills; food supplements, namely, antioxidants; antitumor drugs in the nature of tumor suppressing agents; appetite suppressant pills; appetite suppressants; appetite suppressants for medical purposes; appetite suppressants for veterinary purposes; bacterial preparations for medical use; bacterial preparations for veterinary use; bacteriological culture mediums; bacteriological preparations for medical purposes; bacteriological preparations for medical use; bacteriological preparations for veterinary purposes; bacteriological preparations for veterinary use; biological preparations for medical purposes for the treatment of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; biological preparations for the treatment of cancer; biological tissue cultures for medical purposes; biological tissue cultures for veterinary purposes; biological tissues for implantation being implants comprising living tissue; bouillons for bacteriological cultures; cachets being capsules sold empty for pharmaceutical preparations; capsules sold empty for pharmaceutical preparations; castor oil for medical purposes; cellulose ethers for pharmaceutical purposes; chemical preparations for medical purposes, namely, for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; chemical preparations for pharmaceutical purposes, namely, for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; chemicopharmaceutical preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; cytostatic drugs for medical purposes; decoctions for pharmaceutical purposes, namely, for the treatment of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; dental wax; diagnostic biomarker reagents for medical purposes; diagnostic biomarker reagents for veterinary purposes; diagnostic preparations for medical and veterinary use; diagnostic preparations for medical use; diagnostic preparations for veterinary use; diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic radiopharmaceutical preparations; dietary supplements for animals; dietary supplements for humans; dietetic food and substances adapted for medical or veterinary use, namely, food for human and animal babies; dietetic food and substances adapted for medical or veterinary use; dietetic substances adapted for medical use, namely, food for babies; digestive enzymes being dietary supplements; disinfectants; drugs for medical purposes in the nature of medical preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations, namely, elixirs for the treatment of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; enzyme dietary supplements; enzyme preparations for medical purposes; enzyme preparations for veterinary purposes; enzymes for medical purposes; enzymes for veterinary purposes; esters for pharmaceutical use; ethers for pharmaceutical purposes; ferments for pharmaceutical purposes; ferments for pharmaceutical use; ferments for veterinary purposes; ferments for veterinary use; food esters for pharmaceutical purposes; formic aldehyde for pharmaceutical purposes; formic aldehyde for veterinary purposes; fungicides, herbicides; in vitro diagnostic preparations for medical use; skin lotions for medical purposes; skin lotions for pharmaceutical purposes; material for stopping teeth; material for stopping teeth, dental wax; media for bacteriological cultures; medical and veterinary preparations and products for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; medical preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; medical preparations for slimming purposes; medical vaccines; medicated animal feed; medicinal drinks; medicinal infusions for treating metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; medicinal oils; medicines and pharmaceutical preparations for neurosurgical conditions, brain damage, and neurological operations; medicines and pharmaceutical preparations for neurosurgical conditions, brain damage and brain operations; medicines and pharmaceutical preparations for the treatment of neurosurgical conditions, brain damage, brain operations, and other physical and neurological ailments of the brain; medicines and pharmaceutical preparations for the treatment of neurosurgical conditions, namely, for brain damage and for use in brain operations and other physical and neurological ailments of the brain; medicines and pharmaceutical preparations for use as immunosuppressive agents; medicines and pharmaceutical preparations for use as immunosuppressive agents in organ transplants or other medical and clinical uses of immunosuppressive agents; medicines and pharmaceutical preparations for use as immunosuppressive agents for organ transplants; medicines and pharmaceutical preparations for neurological conditions within the area of neurological intensive care; medicines for human purposes in the nature of medicinal preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; mixed biological preparations for medical purposes, namely, for the treatment of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; nutritional supplements; nutritional supplements for livestock feed; medicated ointments for medical purposes, namely, for treating dermatological conditions; pharmaceutical and veterinary preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical and veterinary preparations, namely, medicines and pharmaceutical preparations for the treatment and prevention of acute and chronic neurological illnesses and conditions; pharmaceutical and veterinary preparations, namely, medicines and pharmaceutical preparations for acute and chronic neurological illnesses and conditions and for preventative treatment; pharmaceutical drugs in the nature of pharmaceutical preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and other preparations for destroying vermin; fungicides and herbicides; pharmaceutical preparations and substances for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for activating cellular function; pharmaceutical preparations for human use for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations for medical purposes and veterinary purposes, namely, for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations for medical use consisting of a cyclosporin as active agent and diluents to treat stroke, traumatic brain or spinal cord injury, and other acute or chronic neurological and neurosurgical conditions; pharmaceutical preparations for medical use consisting of a cyclosporin or another cyclophilin inhibitor as active agent and diluents to treat stroke, traumatic brain or spinal cord injury, and other acute or chronic neurological and neurosurgical conditions; pharmaceutical preparations for skin care; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for the prevention of diseases of the metabolic system; pharmaceutical preparations for the prevention of disorders of the metabolic system; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the prevention of tumors; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for the treatment of diseases caused by bacteria in the nature of antibacterial pharmaceuticals; pharmaceutical preparations for the treatment of diseases of the metabolic system; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of tumors; pharmaceutical preparations for the treatment of viral diseases in the nature of antivirals; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating heatstroke; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for use as immunosuppressive agents; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for neurological conditions within the area of neurological intensive care; pharmaceutical preparations for the prevention of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; pharmaceutical preparations for the treatment of metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; medical and veterinary preparations for metabolic, neurological, cardiovascular and musculoskeletal diseases, cancer, diabetes, mitochondrial diseases, and rare diseases involving mitochondrial and/or metabolic dysfunction; phosphates for pharmaceutical purposes; phosphates for veterinary purposes; medical plasters; medical dressings; potassium salts for medical purposes; potassium salts for veterinary purposes; preparations for destroying vermin; quinine for medical purposes; quinine for veterinary purposes; mineral salts for medical purposes; sanitary preparations for medical purposes; sanitary preparations for veterinary purposes; slimming pills being medical preparations for slimming purposes; sodium salts for medical purposes; sodium salts for veterinary purposes; sulfonamide preparations; tinctures being medicinal drinks for medical purposes; tinctures being medicinal drinks for veterinary purposes; tonics being medicinal drinks; tonics being medicinal drinks for medical use; tonics being medicinal drinks for veterinary use; vaccines; vaccines for human use; veterinary vaccines; drugs and pharmaceutical preparations for acute and chronic neurological diseases and conditions including preventive treatment; the aforementioned rare diseases consisting of Alpers Disease, ALS (Amyotrophic Lateral Sclerosis), Autism, Barth syndrome, Complex I Deficiency (NADH dehydrogenase deficiency), Complex II Deficiency (NADH-CoQ reductase deficiency), Complex III Deficiency (Ubiquinone-cytochrome c oxidoreductase deficiency), Complex IV Deficiency/COX Deficiency, Complex V Deficiency (ATP synthase deficiency), CPEO (Chronic Progressive External Ophthalmoplegia Syndrome), Friedreich's ataxia (FRDA or FA), KSS (Kearns-Sayre Syndrome), Lactic Acidosis, Leigh Disease or Syndrome (Subacute Necrotizing Encephalomyelopathy), LHON (Leber's hereditary optic neuropathy), MELAS (Mitochondrial Encephalomyopathy Lactic Acidosis and Strokelike Episodes), MERRF (Myoclonic Epilepsy and Ragged-Red Fiber Disease), MIDD (Maternally Inherited Diabetes and Deafness), Mitochondrial Myopathy, MNGIE (Myoneurogastointestinal Disorder and Encephalopathy, NARP (Neuropathy, Ataxia, and Retinitis Pigmentosa), Neurodegenerative disorders associated with Parkinson's, Alzheimer's or Huntington's disease, Pearson Syndrome, Pyruvate Carboxylase Deficiency, Pyruvate Dehydrogenase Deficiency, POLG Mutations |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| SN ASSIGNED FOR SECT 66A APPL FROM IB | 2019-01-31 | 1 REPR M: |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2019-02-05 | 2 NWOS I:Incoming Correspondence |
| APPLICATION FILING RECEIPT MAILED | 2019-02-09 | 3 MAFR O:Outgoing Correspondence |
| ASSIGNED TO EXAMINER | 2019-02-13 | 4 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2019-02-26 | 5 CNRT R:Renewal |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2019-02-27 | 6 RFCR E:E-Mail |
| REFUSAL PROCESSED BY MPU | 2019-03-07 | 7 RFRR P: |
| NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 2019-03-08 | 8 RFCS P: |
| REFUSAL PROCESSED BY IB | 2019-03-29 | 9 RFNT P: |
| LIMITATION OF GOODS RECEIVED FROM IB | 2019-09-06 | 10 LIMG M: |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2019-09-06 | 11 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2019-09-06 | 12 ARAA I:Incoming Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-09-06 | 13 TROA I:Incoming Correspondence |
| ASSIGNED TO LIE | 2019-09-12 | 14 ALIE A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-09-16 | 15 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-09-16 | 16 TEME I:Incoming Correspondence |
| FINAL REFUSAL WRITTEN | 2019-10-10 | 17 CNFR R:Renewal |
| FINAL REFUSAL E-MAILED | 2019-10-10 | 18 GNFR O:Outgoing Correspondence |
| NOTIFICATION OF FINAL REFUSAL EMAILED | 2019-10-10 | 19 GNFN O:Outgoing Correspondence |
| LIMITATION FROM THE IB - REQUEST EXAM REVIEW | 2019-11-29 | 20 LIME X:Correction |
| EXAMINERS AMENDMENT -WRITTEN | 2020-04-08 | 21 CNEA R:Renewal |
| EXAMINERS AMENDMENT E-MAILED | 2020-04-08 | 22 GNEA O:Outgoing Correspondence |
| NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2020-04-08 | 23 GNEN O:Outgoing Correspondence |
| EXAMINER'S AMENDMENT ENTERED | 2020-04-08 | 24 XAEC I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2020-04-08 | 25 CNSA O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2020-04-22 | 26 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2020-05-12 | 27 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2020-05-12 | 28 NPUB E:E-Mail |
| NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | 2020-07-01 | 29 OPNR P: |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2020-07-01 | 30 OPNS P: |
| NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | 2020-07-17 | 31 OPNX P: |
| REGISTERED-PRINCIPAL REGISTER | 2020-07-28 | 32 R.PR A:Allowance for Publication |
| CHANGE OF NAME/ADDRESS REC'D FROM IB | 2020-10-23 | 33 ADCH M: |
| FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | 2020-10-28 | 34 FICR P: |
| FINAL DISPOSITION PROCESSED | 2020-11-17 | 35 FIMP P: |
| FINAL DISPOSITION NOTICE SENT TO IB | 2020-11-17 | 36 FICS P: |
| FINAL DECISION TRANSACTION PROCESSED BY IB | 2020-12-05 | 37 FINO P: |
| NEW REPRESENTATIVE AT IB RECEIVED | 2021-10-28 | 38 NREP P: |
| LIMITATION OF GOODS RECEIVED FROM IB | 2022-07-16 | 39 LIMG M: |
| NEW REPRESENTATIVE AT IB RECEIVED | 2023-01-01 | 40 NREP P: |
| CORRECTION UNDER SECTION 7 ¿ PROCESSED | 2023-01-04 | 41 COC. O:Outgoing Correspondence |
| LIMITATION FROM THE IB EXAMINED AND ENTERED | 2023-01-04 | 42 LIME I:Incoming Correspondence |
| NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | 2023-02-07 | 43 NURC C: |
| PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | 2023-09-04 | 44 INPR P: |
| INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | 2023-09-19 | 45 INNA R:Renewal |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 NEUROVIVE 79250595 not registered Live/Pending |
NeuroVive Pharmaceutical AB 2018-11-09 |
 NEUROVIVE 79047227 3520893 Dead/Cancelled |
NeuroVive Pharmaceutical AB 2007-09-07 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 